spacer
home > pmps > autumn 2018 > connecting medications
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Connecting Medications

Medication noncompliance is becoming an increasingly focussed concern in the healthcare sector for diverse reasons. Various studies targeting this issue in recent years have confirmed a particular picture: if the majority of research outcomes are correct and more than 50% of patients do not take their medications as prescribed, the economic and personal costs of inadequate patient adherence are enormous (1). In the US alone, the costs of medication noncompliance to the healthcare system are estimated to range between US $100 billion and US $290 billion annually (2). Furthermore, approximately 125,000 deaths and more than 10% of US hospitalisations per year are directly linked to nonadherence reasons (3). In addition to the adverse effects on public or private healthcare systems, medication noncompliance significantly impacts the profitability of pharmaceutical manufacturers.

Changing Traditional Business Models

Increasing cost pressures on healthcare systems and pharma companies from the market or policymakers, stringent regulatory requirements, and progressive digitalisation are massively changing traditional business models. From a blockbuster-driven past, a clear trend towards a pharma industry increasingly committed to producing value-added pharmaceuticals is now visibly emerging. Outcome-based drug pricing may help the pharma industry justify expensive therapies that often cost thousands of euros or dollars a month. On the other hand, healthcare systems are looking for ways to become more efficient by only paying the costs of medicines with proven positive effects. In this context, patient behaviour is of particular importance, as adherence to the prescribed medication decisively contributes to therapy, as well as, ultimately, economic success in clinical trials and commercial products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mathias Held is Business Development Manager for Patient Compliance Monitoring Solutions at Schreiner MediPharm, a business unit of Schreiner Group. He is in charge of developing new markets and business opportunities with a strong focus on smart packaging. Mathias has a degree in media technology from the Leipzig University of Applied Sciences, Germany.
spacer
Mathias Held
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase

AirBridgeCargo expands its passive pharma solutions in partnership with SkyCell as it achieves the two-fold volume increase AirBridgeCargo Airlines (ABC), one of the leaders in transportation of pharmaceutical products by air, and Zurich-based cold-chain ULD manufacturer SkyCell have sealed their partnership for the lease of all types of SkyCell containers to meet the demand for evolving volumes of passive pharmaceutical shipments, which reached around 3,500 tonnes for 1Q 2019 YOY and demonstrated a two-fold increase.
More info >>

White Papers

Spotlight on Quality in Study Startup

Oracle Health Sciences

This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement